12:00 AM
 | 
Jan 06, 2014
 |  BioCentury  |  Finance

X marks the spot

Trio of investors back newco Alexar, topical LXR agonist for inflammation
X marks the spot

Alexar Therapeutics Inc. isn't going after a novel target - LXR has been around for decades - but the newco is one of only two biotechs developing a topical agonist of the liver X receptor. Investors backed Alexar with a $21.5 million series A round to develop lead topical agonist A-110 in inflammatory cutaneous...

Read the full 273 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >